I am a Healthcare Professional outside the US and UK

I am a Healthcare Professional outside the US and UK

Click here for international medical scientific information about Oncology for Healthcare Professionals.

I am not a Healthcare Professional and I am outside the US and the UK

I am not a Healthcare Professional and I am outside the US and the UK

Click here for general international information for patients, caregivers and the general public.

Country-specific medical scientific information

Country-specific medical scientific information

Country-specific medical scientific information for Healthcare Professionals.

This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

InOncology.com

ESMO, Munich, Germany, 19-23 October 2018

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: final analysis of the global Phase III LUX-Lung 8 trial

Glenwood D Goss, Manuel Cobo, Shun Lu, Konstantinos Syrigos, Ki Hyeong Lee, Erdem Göker, Vassilis Georgoulias, Dolores Isla, Alessandro Morabito, Young J Min, Andrea Ardizzoni, Agnieszka Cseh, Shaun Bender, Enriqueta Felip

ESMO LL8 Final analysis poster
1200.125 LUX-Lung 8 ESMO 2018 additional Content

RELATED MATERIALS

Learn more about the science behind this poster in the videos, papers and other materials below.

Afatinib treatment in squamous cell lung cancer - Video Abstract

Vera Hirsh

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.

Soria JC, et al. Lancet Oncol 2015;16(8):897–907

Impact of ErbB Mutations on Clinical Outcomes in Patients with Squamous Cell Carcinoma of the Lung Treated with Afatinib or Erlotinib 

Goss GD, et al. JAMA Oncol. doi:10.1001/jamaoncol.2018.0775

FOR HEALTHCARE PROFESSIONALS ONLY.

In the European Union, afatinib is approved for use in TKI-naive adults with locally advanced or metastatic NSCLC with activating EGFR mutations and in patients with NSCLC of squamous histology on or after chemotherapy. It is not yet approved in other indications.

Disclaimer